Gwenn Hansen Sells 3,214 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,214 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $16.65, for a total transaction of $53,513.10. Following the completion of the transaction, the insider owned 120,399 shares in the company, valued at $2,004,643.35. This represents a 2.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gwenn Hansen also recently made the following trade(s):

• On Friday, January 30th, Gwenn Hansen sold 4,895 shares of Nurix Therapeutics stock. The stock was sold at an average price of $16.60, for a total transaction of $81,257.00.

Nurix Therapeutics Stock Performance

Shares of Nurix Therapeutics stock opened at $16.81 on Friday. Nurix Therapeutics, Inc. has a 52-week low of $8.19 and a 52-week high of $22.50. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -5.32 and a beta of 1.88. The company’s 50 day moving average price is $15.83 and its 200-day moving average price is $15.99.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Wednesday, April 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.03). Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%.The firm had revenue of $6.25 million during the quarter, compared to the consensus estimate of $14.25 million. As a group, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

NRIX has been the topic of several recent analyst reports. BTIG Research restated a “buy” rating and issued a $30.00 target price on shares of Nurix Therapeutics in a report on Thursday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $26.00 price target on shares of Nurix Therapeutics in a research note on Thursday, April 23rd. Wells Fargo & Company dropped their price target on Nurix Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Thursday, April 9th. Piper Sandler raised their price target on Nurix Therapeutics from $32.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday, January 29th. Finally, Morgan Stanley set a $36.00 price target on Nurix Therapeutics and gave the stock an “overweight” rating in a research note on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Nurix Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $30.46.

Hedge Funds Weigh In On Nurix Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in NRIX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Nurix Therapeutics by 11.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock valued at $593,000 after buying an additional 5,286 shares during the period. Millennium Management LLC lifted its position in Nurix Therapeutics by 106.2% during the first quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock valued at $10,388,000 after buying an additional 450,262 shares during the period. Goldman Sachs Group Inc. lifted its position in Nurix Therapeutics by 9.5% during the first quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock valued at $6,029,000 after buying an additional 44,002 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Nurix Therapeutics by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock valued at $1,895,000 after buying an additional 12,817 shares during the period. Finally, Creative Planning purchased a new position in Nurix Therapeutics during the second quarter valued at $187,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.